Stock JBCHEPHARM J. B. CHEMICALS & PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings J. B. Chemicals & Pharmaceuticals Limited NSE India S.E.

Equities

JBCHEPHARM

INE572A01036

Delayed NSE India S.E.
Other stock markets
 10:09:41 15/05/2024 BST 		5-day change 1st Jan Change
1,815 INR +0.96% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited +0.86% +11.65%
05-06 KKR to buy India's Healthium Medtech at $839 million valuation, sources say RE
04-26 J. B. Chemicals & Pharmaceuticals Limited Receives Order from Joint Commissioner State Tax, Lucknow II, Lucknow CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • With an expected P/E ratio at 46.48 and 37.21 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
J. B. CHEMICALS & PHARMACEUTICALS LIMITED Stock J. B. Chemicals & Pharmaceuticals Limited
+11.65% 3.33B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.79% 588B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.21% 239B
B+
NOVARTIS AG Stock Novartis AG
+9.91% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-7.20% 200B
A+
AMGEN INC. Stock Amgen Inc.
+8.12% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-1.42% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. JBCHEPHARM Stock
  4. JBCHEPHARM Stock
  5. Ratings J. B. Chemicals & Pharmaceuticals Limited